TNFRSF1B and melanoma: Both TNFRII (Group I) and OX40 (Group II) are targets for immunotherapy and may be used to manipulate T‐cell responses, and currently, clinical trials are ongoing for melanoma and other solid cancers (Croft et al, 2009).